18F-FLT PET/CT作为原发性软组织肉瘤疾病特异性生存的预后影像生物标志物
本研究为一项单中心单臂前瞻性临床试验的10年随访,评估18F-FLT PET/CT在新辅助治疗及手术切除的软组织肉瘤患者中作为长期总生存和疾病特异性生存早期预后影像生物标志物的价值。共26例患者行治疗前PET1,其中16例原发STS行新辅助治疗后PET2。原发STS亚组分析中,PET1肿瘤SUVmax低者(<8 vs ≥8)DSS显著更长(P=0.034)。结论认为18F-FLT PET可作为原发STS患者DSS的基线预后影像生物标志物。
要点
- 原发STS患者治疗前18F-FLT PET肿瘤SUVmax<8者疾病特异性生存显著更长(P=0.034)。
- 总体队列中PET1 SUVmax<8.5者总生存更长(未达到 vs 49.7个月,P=0.0064)。
- 新辅助治疗后PET2未见与DSS或总生存显著相关的18F-FLT PET反应阈值。
核心结论
- 18F-FLT PET可能作为原发STS患者疾病特异性生存的基线预后影像生物标志物。
研究设计与样本
- 本研究为既往单中心、单臂前瞻性临床试验的10年随访。
- 26例患者行治疗前18F-FLT PET/CT(PET1),其中16例原发STS行新辅助治疗后PET2。
- 对治疗后病理标本评估肿瘤坏死或纤维化及Ki-67和胸苷激酶1表达,并采用最大选择法确定PET和病理因素的截断值。
主要发现
- 总体队列中,PET1肿瘤SUVmax低者(<8.5)较高者(≥8.5)总生存更长(未达到 vs 49.7个月,P=0.0064)。
- 总体队列中DSS风险比趋势接近显著性(P=0.096)。
- 原发STS亚组分析中,PET1肿瘤SUVmax低者(<8)较高者(≥8)DSS显著更长(P=0.034)。
- 新辅助治疗后PET2未见与DSS或总生存显著相关的18F-FLT PET反应阈值。
关键数值与推荐
- PET1肿瘤SUVmax截断值:总体队列总生存分析为≥8.5 vs <8.5(P=0.0064)。
- PET1肿瘤SUVmax截断值:原发STS亚组DSS分析为≥8 vs <8(P=0.034)。
临床怎么用
- 治疗前18F-FLT PET/CT肿瘤SUVmax可能有助于原发STS患者的预后分层。
- 新辅助治疗后18F-FLT PET/CT反应评估未显示与生存的显著关联,暂不宜据此调整治疗。
局限性
- 样本量小(PET1共26例,PET2仅16例原发STS),结果需更大样本验证。
- 为单中心单臂研究,存在选择偏倚可能。
- 总体队列DSS分析仅显示趋势显著性(P=0.096)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The purpose of this study was to evaluate 18F-FLT PET/CT as an early prognostic imaging biomarker of long-term overall survival and disease-specific survival (DSS) in soft-tissue sarcoma (STS) patients treated with neoadjuvant therapy (NAT) and surgical resection. Methods: This was a 10-y follow-up of a previous single-center, single-arm prospective clinical trial. Patients underwent 18F-FLT PET/CT before treatment (PET1) and after NAT (PET2). Posttreatment pathology specimens were assessed for tumor necrosis or fibrosis and for Ki-67 and thymidine kinase 1 expression. Maximally selected cutoffs for PET and histopathologic factors were applied. Survival was calculated from the date of subject consent to the date of death or last follow-up. Results: The study population consisted of 26 patients who underwent PET1; 16 of the 26 with primary STS underwent PET2. Thirteen deaths occurred during a median follow-up of 104 mo. In the overall cohort, overall survival was longer in patients with a low than a high PET1 tumor SUVmax (dichotomized by an SUVmax of ≥8.5 vs. <8.5: not yet reached vs. 49.7 mo; P = 0.0064). DSS showed a trend toward significance (P = 0.096). In a subanalysis of primary STS, DSS was significantly longer in patients with a low PET1 tumor SUVmax (dichotomized by an SUVmax of ≥8 vs. <8; P = 0.034). There were no significant 18F-FLT PET response thresholds corresponding to DSS or overall survival after NAT at PET2. Conclusion:18F-FLT PET may serve as a prognostic baseline imaging biomarker for DSS in patients with primary STS.
引用
- Crompton JG, Armstrong WR, Eckardt MA, et al. 18F-FLT PET/CT as a Prognostic Imaging Biomarker of Disease-Specific Survival in Patients with Primary Soft-Tissue Sarcoma. J Nucl Med. 2021. PMID: 34593596. doi:10.2967/jnumed.121.262502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。